All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
What might be the advantages and disadvantages of treating with daratumumab upfront?
Featured
Bookmark this article
During the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple Myeloma Hub was pleased to speak to Meral Beksac, Ankara University, Ankara, TR. We asked, What might be the advantages and disadvantages of treating with daratumumab upfront?
What might be the advantages and disadvantages of treating with daratumumab upfront?
In this video, Beksac discusses the recent relevant data from ASH 2021 that compared the use of frontline daratumumab with other regimens. Beksac comments on the differences in survival rates when daratumumab is given as a frontline treatment, compared with VRd and Rd regimens. Finally, Beksac talks about the Cassiopeia trial.
Your opinion matters
27 votes - 5 days left ...
Related articles
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox